Brief: In8bio Receives FDA Orphan Drug Designation For Inb-400/410 For The Treatment Of Newly Diagnosed Glioblastoma

IN8bio

25/04/2023 13:51

IN8BIO, Inc.  INAB.O :
    * IN8BIO RECEIVES FDA ORPHAN DRUG DESIGNATION FOR
INB-400/410 FOR
THE TREATMENT OF NEWLY DIAGNOSED GLIOBLASTOMA
    * IN8BIO RECEIVES FDA ORPHAN DRUG DESIGNATION FOR
INB-400/410 FOR
THE TREATMENT OF NEWLY DIAGNOSED GLIOBLASTOMA
    * IN8BIO, INC. - ANTICIPATE ENROLLING OUR FIRST PHASE 2
PATIENTS
FOR INB-400 LATER THIS YEAR
    * IN8BIO, INC. - FOR INB-400 PATIENT ENROLLMENT IS EXPECTED
TO
BEGIN IN SECOND HALF OF 2023

Source text for Eikon:  ID:nGNX288G23 
Further company coverage:  INAB.O